Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

Maddison, Paul; Newsom‐Davis, John; Mills, Kerry; Souhami, Robert L.

doi:10.1016/s0140-6736(05)76153-5

Cited by 224 publications

(111 citation statements)

References 3 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Patients with occult or advanced tumors may develop a wide variety of syndromes, varying from myasthenia gravis to cerebellar degeneration, owing to acquired cellular and/or humoral immunity to antigens expressed by the tumor 7 . In small-cell lung cancer, the occurrence of paraneoplastic syndromes can portend prolonged survival 8 . These observations raise the question of whether deliberate attempts to provoke paraneoplastic syndrome should be attempted, and, on a related note, whether the occurrence of these syndromes will increase with increasing numbers of cancer patients exposed to immune-checkpointblockade administration.…”

Section: Volume 23 | Number 5 | May 2017 Nature Medicine P E R S P E mentioning

confidence: 99%

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June

Warshauer

Bluestone

2017

Nat Med

382

308

View full text Add to dashboard Cite

Section: Volume 23 | Number 5 | May 2017 Nature Medicine P E R S P E mentioning

confidence: 99%

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June

Warshauer

Bluestone

2017

Nat Med

382

308

View full text Add to dashboard Cite

“…The oncogenic proteins L-Myc and C-Myc have been found to elicit autoantibodies in a small percentage of patients (1,6). There is some evidence that occurrence of autoantibodies in lung cancer is of prognostic relevance (7)(8)(9). Remarkably, tumor regression has been demonstrated in some patients with small cell lung carcinoma and autoantibodies to onconeural antigens (10,11).…”

mentioning

confidence: 99%

An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer

Brichory

Misek

Yim

et al. 2001

Proc. Natl. Acad. Sci. U.S.A.

283

204

View full text Add to dashboard Cite

The identification of circulating tumor antigens or their related autoantibodies provides a means for early cancer diagnosis as well as leads for therapy. The purpose of this study was to identify proteins that commonly induce a humoral response in lung cancer by using a proteomic approach and to investigate biological processes that may be associated with the development of autoantibodies. Aliquots of solubilized proteins from a lung adenocarcinoma cell line (A549) and from lung tumors were subjected to two-dimensional PAGE, followed by Western blot analysis in which individual sera were tested for primary antibodies. Sera from 54 newly diagnosed patients with lung cancer and 60 patients with other cancers and from 61 noncancer controls were analyzed. Sera from 60% of patients with lung adenocarcinoma and 33% of patients with squamous cell lung carcinoma but none of the noncancer controls exhibited IgG-based reactivity against proteins identified as glycosylated annexins I and͞or II. Immunohistochemical analysis showed that annexin I was expressed diffusely in neoplastic cells in lung tumor tissues, whereas annexin II was predominant at the cell surface. Interestingly, IL-6 levels were significantly higher in sera of antibody-positive lung cancer patients compared with antibody-negative patients and controls. We conclude that an immune response manifested by annexins I and II autoantibodies occurs commonly in lung cancer and is associated with high circulating levels of an inflammatory cytokine. The proteomic approach we have implemented has utility for the development of serum-based assays for cancer diagnosis as we report in this paper on the discovery of antiannexins I and͞or II in sera from patients with lung cancer.

show abstract

“…Small cell lung carcinomas derive from neuroendocrine cells, which often express voltage-gated calcium channels and other neuronal features including AChRs (Codingnola et al, 1994). LEMS is a relatively beneficial side effect of an effective immune response to the tumor, which holds this normally rapidly fatal tumor in check sometimes for years after the autoantibodies to voltage-gated calcium channels initially impair neuromuscular transmission (Maddison et al, 1999). The thymic tumor cells seen in MG patients are not such an obvious source of AChR immunogen.…”

Section: Cause Of the Autoimmune Responsementioning

confidence: 99%

Autoimmune diseases involving nicotinic receptors

Lindstrom

2002

J. Neurobiol.

View full text Add to dashboard Cite

ABSTRACT:The antibody-mediated autoimmune response to ␣1 muscle nicotinic acetylcholine receptors that causes myasthenia gravis is one of the best characterized autoimmune diseases. Antibodymediated autoimmune responses to neuronal nicotinic receptors are just beginning to be discovered and characterized. One of these causes dysautonomia through antibodies to ␣3 nicotinic receptors of autonomic ganglia. Another causes pemphigus through antibodies to ␣9 nicotinic receptors in skin. Other autoimmune responses to nicotinic receptors may be discovered as the many functional roles of nicotinic receptors are revealed.

show abstract

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

Cited by 224 publications

References 3 publications

Is autoimmunity the Achilles' heel of cancer immunotherapy?

Is autoimmunity the Achilles' heel of cancer immunotherapy?

An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer

Autoimmune diseases involving nicotinic receptors

Contact Info

Product

Resources

About